CAMKK2 and metabolic dysfunction-associated steatotic liver disease: In this context, CAMKK2-mediated downregulation of SDHB and reduced OXPHOS function in hepatocyte-like HepG2 cells [94] becomes physiologically relevant as it supports the findings that pharmacological treatment with STO-609, a selective small-molecule inhibitor of CAMKK2, conferred protection against NAFLD in a Streptozotocin and high fat-diet induced mouse model [76].